1. GPCR/G Protein
  2. mGluR

Topiramate (Synonyms: McN 4853; RWJ 17021)

Cat. No.: HY-B0122 Purity: >98.0%
Data Sheet SDS Handling Instructions

Topiramate is an anticonvulsant that antagonizes GluR5 receptors and acts as a positive allosteric modulator of GABA receptor-mediated currents.

For research use only. We do not sell to patients.
Topiramate Chemical Structure

Topiramate Chemical Structure

CAS No. : 97240-79-4

Size Price Stock Quantity
Free Sample (0.5-1 mg)   Apply now  
10 mM * 1 mL in DMSO $83 In-stock
100 mg $75 In-stock
500 mg $225 In-stock
1 g   Get quote  
5 g   Get quote  

* Please select Quantity before adding items.

  • Biological Activity

  • Protocol

  • Technical Information

  • Purity & Documentation

  • References

Description

Topiramate is an anticonvulsant that antagonizes GluR5 receptors and acts as a positive allosteric modulator of GABA receptor-mediated currents. Target: GluR5 receptor; GABA receptor Topiramate (Topamax) is a structurally novel broad-spectrum antiepileptic drug (AED) with established efficacy as monotherapy or adjunctive therapy in the treatment of adult and paediatric patients with generalised tonic-clonic seizures, partial seizures with or without generalised seizures, and seizures associated with Lennox-Gastaut syndrome [1]. topiramate has been believed to be a type of antiepileptic drug that blocks spread of seizures. Thus far, the mechanisms of its actions have been proven to include use-dependent inhibition of voltage-dependent Na+ channels in neurons, potentiation of GABA (gamma-amino-butyric acid)-induced Cl- influx, and inhibitory effects on inward currents by antagonizing kainate/alpha-amino-3-hydroxy-5-methylisoxazole-4-propionic acid (AMPA) receptors [2]. Topiramate (median average dosage 5.1 mg/kg/day) was also found to be useful as adjunctive therapy in the management of Lennox-Gastaut syndrome and significantly reduced the mean frequency of drop attacks by 14.8% compared with an increase of 5.1% with placebo. Further gains in seizure control were made in a nonblind extension of this trial where the mean topiramate dosage was 10 mg/kg/day. Nine of 11 patients in 1 pilot trial of children with otherwise intractable West syndrome, and 5 of 10 in another, achieved a > or =50% reduction in seizure rate with topiramate (target dosage up to 24 mg/kg/day) [3]. Clinical indications: Epilepsy; Lennox Gastaut syndrome; Migraine; Seizure disorder Toxicity:abdominal pain; agitation; blurred vision; convulsions; depression; dizziness; double vision; drowsiness; impaired coordination; impaired mental activity; low blood pressure; reduced consciousness; severe diarrhea; sluggishness and speech problems.

Clinical Trial
NCT Number Sponsor Condition Start Date Phase
NCT02169830 St. Louis University Migraine Disorders June 2014
NCT00606411 Massachusetts General Hospital Sleep-Related Eating Disorder January 2008 Early Phase 1
NCT00300742 University of Virginia Alcohol Dependence|Binge Eating March 2006 Phase 2
NCT01135602 Chiang Mai University Alcohol Dependence July 2010 Phase 4
NCT00846495 Clinvest|Endo Pharmaceuticals|Cady, Roger, M.D. Migraine August 2009 Phase 4
NCT01145677 Chiang Mai University Alcohol Dependence June 2010 Phase 2|Phase 3
NCT01682681 Janssen Korea, Ltd., Korea Epilepsy July 2007 Phase 4
NCT01408641 University of Maryland|VA Office of Research and Development Alcohol Dependence|Alcoholism|Alcohol Abuse|Alcohol Use Disorder|PTSD|Posttraumatic Stress Disorder September 2012
NCT00394095 University of Cincinnati|Eli Lilly and Company Bipolar Disorder|Weight Gain December 2006 Phase 4
NCT00626925 UConn Health|National Institute on Alcohol Abuse and Alcoholism (NIAAA)|National Center for Research Resources (NCRR) Alcohol Drinking February 2008 Phase 4
NCT00203463 Tuscaloosa Research & Education Advancement Corporation|Ortho-McNeil Janssen Scientific Affairs, LLC PTSD July 2001 Phase 4
NCT03120468 Nassima Ait-Daoud Tiouririne|University of Virginia Alcoholism May 1, 2017 Early Phase 1
NCT02878798 University of Utah|National Institute of Neurological Disorders and Stroke (NINDS)|NeuroNEXT Network Cryptogenic Sensory Peripheral Neuropathy September 2017 Phase 2
NCT02808533 Centre for Addiction and Mental Health|Ontario Ministry of Health and Long Term Care Schizophrenia, Schizoaffective Disorder April 2016
NCT00902473 Ranbaxy Laboratories Limited|Ranbaxy Inc. Healthy September 2001
NCT01110434 Brown University|National Institute on Drug Abuse (NIDA) Cannabis Abuse|Cannabis Dependence December 2009 Phase 2
NCT01641445 Brown University Alcohol Drinking July 2012 Phase 1|Phase 2
NCT00901784 Ranbaxy Laboratories Limited|Ranbaxy Inc. Healthy September 2001
NCT02138058 University of Sao Paulo Compulsive Shopping January 2015 Phase 2
NCT00802412 VA Office of Research and Development Nicotine Dependence|Alcohol Dependence January 2009 Phase 2
NCT00167245 Kyle Kampman|National Institute on Alcohol Abuse and Alcoholism (NIAAA)|University of Pennsylvania Alcoholism|Cocaine Dependence September 2004 Phase 2
NCT00223626 Bankole Johnson|National Institute on Drug Abuse (NIDA)|University of Virginia Cocaine-Related Disorders January 2007 Phase 2
NCT02424318 SMG-SNU Boramae Medical Center Migraine Disorders December 2008 Phase 4
NCT01087736 University of California, San Francisco|United States Department of Defense|VA Office of Research and Development PTSD|Alcohol Abuse|Alcoholism April 2010 Phase 4
NCT01799590 Janssen Pharmaceutical K.K. Migraine August 2007 Phase 2
NCT02810483 Assistance Publique - Hôpitaux de Paris Prader-Willi Syndrome December 2012 Phase 3
NCT00216619 Janssen Pharmaceutica N.V., Belgium Migraine November 2003 Phase 3
NCT00572117 Stanford University|National Institute on Alcohol Abuse and Alcoholism (NIAAA) Bipolar Disorder|Alcoholism|Alcohol Dependence August 2007 Phase 4
NCT01689649 Johnson & Johnson Pte Ltd Epilepsy May 2008 Phase 4
NCT01859013 University of Minnesota - Clinical and Translational Science Institute Obesity, Morbid|Obesity|Weight Loss June 2013 Phase 2
NCT01229735 UCB Korea Co., Ltd.|UCB Pharma Epilepsy November 2010 Phase 4
NCT00550394 University of Cincinnati|National Institute on Alcohol Abuse and Alcoholism (NIAAA) Bipolar Disorder|Alcohol Abuse April 2008 Phase 4
NCT01789047 Rush University Medical Center|Michael J. Fox Foundation for Parkinson's Research Idiopathic Parkinson's Disease|Drug Induced Dyskinesia March 2013 Phase 2
NCT02884050 University of Florida Alteration of Cognitive Function April 2009 Phase 1
NCT00345371 National Institute on Drug Abuse (NIDA) Methamphetamine April 2006 Phase 2
NCT01764685 University of Pennsylvania Heavy Drinking|HIV|Alcohol Dependence January 2013 Phase 2
NCT00732108 University of California, San Francisco|American Academy of Otolaryngology-Head and Neck Surgery Foundation Migraine|Headache|Dizziness November 2008
NCT01081795 Janssen Pharmaceutical K.K. Migraine April 2007 Phase 2
NCT00986336 Johnson & Johnson Pharmaceutical Research & Development, L.L.C. Bipolar Disorder February 2001 Phase 1
NCT00216606 Janssen Pharmaceutica N.V., Belgium Migraine December 2003 Phase 3
NCT00297336 Janssen Cilag Pharmaceutica S.A.C.I., Greece Migraine Disorders March 2005
NCT01765218 University of California, Davis Hypoxic Ischemic Encephalopathy February 2013 Phase 1|Phase 2
NCT02639598 Taipei Veterans General Hospital, Taiwan Chronic Migraine June 2012 Phase 4
NCT00939692 Torrent Pharmaceuticals Limited Healthy January 2007 Phase 1
NCT03018704 VA Office of Research and Development Alcohol Use Disorder August 1, 2017 Phase 4
NCT00988481 Neuropsychiatric Research Institute, Fargo, North Dakota Bulimia Nervosa September 2009 Phase 4
NCT02191579 Allergan Migraine Disorders August 2014 Phase 4
NCT02074904 University of Pennsylvania Alcohol Drinking May 2015 Phase 2
NCT00753493 University of Minnesota - Clinical and Translational Science Institute Epilepsy|Migraines August 2008 Phase 1
NCT01060111 Janssen Korea, Ltd., Korea Migraine July 2006 Phase 4
NCT01384279 Beitou Armed Forces Hospital, Taipei, Taiwan Obesity May 2011
NCT02273804 Assistance Publique - Hôpitaux de Paris Obese Children and Adolescents June 2016 Phase 3
NCT02239913 University of Kentucky|National Institute on Drug Abuse (NIDA) Cocaine Use Disorder September 2014 Phase 1
NCT01241019 Azienda Ospedaliero, Universitaria Meyer|Azienda Ospedaliero, Universitaria Pisana Hypoxic Ischemic Encephalopathy February 2010 Phase 2
NCT00231673 Johnson & Johnson Pharmaceutical Research & Development, L.L.C. Diabetic Neuropathies|Diabetes Mellitus, Type 2|Polyneuropathies July 2001 Phase 2
NCT01627860 Johnson & Johnson Taiwan Ltd Epilepsy February 2010 Phase 4
NCT01834404 Mayo Clinic|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) Obesity April 2013 Phase 4
NCT00393978 University of Cincinnati|National Institute on Drug Abuse (NIDA) Bipolar Disorder|Cannabis-Related Disorder November 2006 Phase 4
NCT02201251 Janssen Research & Development, LLC Epilepsy October 6, 2014 Phase 3
NCT00233012 Johnson & Johnson Pharmaceutical Research & Development, L.L.C. Seizures June 2005 Phase 1
NCT00986128 Johnson & Johnson Pharmaceutical Research & Development, L.L.C. Bipolar Disorder March 2001 Phase 1
NCT00939705 Torrent Pharmaceuticals Limited Healthy Phase 1
NCT00685178 Johns Hopkins University|National Institute on Drug Abuse (NIDA) Cocaine Dependence February 2007 Phase 2
NCT00755716 UConn Health|National Center for Research Resources (NCRR) Tobacco Dependence April 2006 Phase 3
NCT01700387 Cady, Roger, M.D.|Allergan Chronic Migraine October 2012 Phase 4
NCT00956696 Chinese University of Hong Kong Epilepsy May 2009 Phase 4
NCT00463775 Elizabeth Ralevski|Yale University Alcohol Dependence|Borderline Personality Disorder March 2007 Phase 3
NCT00182455 Hamilton Health Sciences Corporation|Janssen-Ortho Inc., Canada|McMaster University Social Phobia March 2004 Phase 4
NCT00421603 New York State Psychiatric Institute|National Institute on Drug Abuse (NIDA) Cocaine Dependence February 2007 Phase 2
NCT00211744 Icahn School of Medicine at Mount Sinai|Ortho-McNeil Pharmaceutical Obsessive-Compulsive Disorder August 2004 Phase 4
NCT00370188 Centre for Addiction and Mental Health Gambling September 2006 Phase 2
NCT00182520 Hamilton Health Sciences Corporation|Janssen-Ortho Inc., Canada|McMaster University Obsessive Compulsive Disorder January 2002 Phase 4
NCT00249691 Bankole Johnson|National Institute on Drug Abuse (NIDA)|University of Virginia Cocaine-Related Disorders October 2005 Phase 3
NCT00905164 Teva Pharmaceuticals USA Healthy June 2002 Phase 1
NCT00153699 Chinese University of Hong Kong|Hong Kong Eye Hospital Glaucoma, Angle-Closure September 2004 Phase 4
NCT00297349 Janssen Cilag Pharmaceutica S.A.C.I., Greece Seizures|Epilepsy November 2003
NCT00266604 Johnson & Johnson Pharmaceutical Research & Development, L.L.C.|Ortho-McNeil Neurologics, Inc. Epilepsy|Seizures|Epilepsies, Partial|Epilepsy, Generalized|Seizures, Tonic-Clonic December 2005 Phase 4
NCT00231556 Johnson & Johnson Pharmaceutical Research & Development, L.L.C. Epilepsy|Seizures|Epilepsies, Partial|Epilepsy, Generalized|Epilepsy, Tonic-Clonic July 1999 Phase 3
NCT00210574 Johnson & Johnson Pharmaceutical Research & Development, L.L.C.|Ortho-McNeil Neurologics, Inc. Epilepsy, Absence March 2005 Phase 2
NCT00794313 Oregon Health and Science University Parkinson's Disease September 2009
NCT00231608 Johnson & Johnson Pharmaceutical Research & Development, L.L.C. Obesity December 1998 Phase 2
NCT00448825 Bankole Johnson|National Institute on Drug Abuse (NIDA)|University of Virginia Alcohol Dependence|Cocaine Dependence March 2007 Phase 3
NCT00725920 Federal University of São Paulo|Fundação de Amparo à Pesquisa do Estado de São Paulo Posttraumatic Stress Disorder January 2007 Phase 4
NCT00035802 Johnson & Johnson Pharmaceutical Research & Development, L.L.C. Bipolar Disorder|Affective Disorders, Psychotic|Mood Disorders|Mental Disorders January 2002 Phase 3
NCT02371889 University of Pennsylvania|National Institute on Alcohol Abuse and Alcoholism (NIAAA)|National Institutes of Health (NIH)|Department of Health and Human Services|Corporal Michael J. Crescenz VA Medical Center Alcoholism January 2015 Phase 2
NCT01749215 University of California, San Francisco|United States Department of Defense|San Francisco Veterans Affairs Medical Center|Northern California Institute of Research and Education Alcohol Dependence|Posttraumatic Stress Disorder (PTSD) February 2013 Phase 4
NCT00598923 University of Pennsylvania Traumatic Brain Injury|Epilepsy November 2004 Early Phase 1
NCT01843699 University of Sao Paulo Pathological Gambling June 2009 Phase 2
NCT00243984 Northeastern Ohio Universities College of Medicine|Akron General Medical Center|Forum Health|Aultman Health Foundation|St. Elizabeth Health Center|Mercy Medical Center Metabolic Syndrome X|Diabetes Mellitus, Type 2 March 2005 Phase 3
NCT00905606 Teva Pharmaceuticals USA Healthy June 2001 Phase 1
NCT00245583 Icahn School of Medicine at Mount Sinai|Ortho-McNeil, Inc. Pathological Gambling Phase 4
NCT00905346 Teva Pharmaceuticals USA Healthy June 2002 Phase 1
NCT00230698 Johnson & Johnson Pharmaceutical Research & Development, L.L.C. Epilepsy|Epilepsies, Partial|Seizures November 1995 Phase 3
NCT00200941 Neurocare|Ortho-McNeil Pharmaceutical Restless Legs Syndrome August 2001 Phase 4
NCT00253175 Johnson & Johnson Pharmaceutical Research & Development, L.L.C.|Ortho-McNeil Neurologics, Inc. Vascular Headaches|Migraine October 2000 Phase 3
NCT01182766 University of Virginia|National Institute on Alcohol Abuse and Alcoholism (NIAAA)|M.D. Anderson Cancer Center|University of California, San Diego Alcohol Dependence|Nicotine Dependence September 2011 Phase 2|Phase 3
NCT00904943 Teva Pharmaceuticals USA Healthy June 2002 Phase 1
NCT00905567 Teva Pharmaceuticals USA Healthy June 2001 Phase 1
NCT00280839 Lindner Center of HOPE|Ortho-McNeil Neurologics, Inc.|University of Cincinnati Smoking Cessation Phase 3
NCT00011804 National Institute of Dental and Craniofacial Research (NIDCR)|National Institutes of Health Clinical Center (CC) Sciatica February 2001 Phase 2
NCT00286988 Monarch Medical Research|Ortho-McNeil Neurologics, Inc. Vomiting March 2006 Phase 4
NCT00236743 Johnson & Johnson Pharmaceutical Research & Development, L.L.C. Epilepsy|Epilepsies, Partial|Seizures June 1994 Phase 3
NCT00768677 The Zucker Hillside Hospital Eating Disorders|Bulimia Nervosa July 2003
NCT00236418 Johnson & Johnson Pharmaceutical Research & Development, L.L.C. Epilepsy|Seizures December 1994 Phase 3
NCT00648934 Mylan Pharmaceuticals Healthy November 2005 Phase 1
NCT00649740 Mylan Pharmaceuticals Healthy November 2005 Phase 1
NCT00231595 Johnson & Johnson Pharmaceutical Research & Development, L.L.C. Migraine|Common Migraine|Classic Migraine|Headache March 2001 Phase 3
NCT00236704 Johnson & Johnson Pharmaceutical Research & Development, L.L.C. Epilepsy|Seizures March 1994 Phase 3
NCT00649467 Mylan Pharmaceuticals Healthy November 2005 Phase 1
NCT00035230 Johnson & Johnson Pharmaceutical Research & Development, L.L.C. Bipolar Disorder July 2001 Phase 3
NCT00037674 Johnson & Johnson Pharmaceutical Research & Development, L.L.C. Bipolar Disorder January 2001 Phase 3
NCT00266591 Johnson & Johnson Pharmaceutical Research & Development, L.L.C. Epilepsy|Seizures October 1992 Phase 3
NCT00236509 Johnson & Johnson Pharmaceutical Research & Development, L.L.C. Migraine|Common Migraine|Classic Migraine|Headache February 2001 Phase 3
NCT00701493 Johnson & Johnson Pharmaceutical Research & Development, L.L.C. Epilepsy November 2004 Phase 1
NCT01750268 University of California, San Francisco|United States Department of Defense|Northern California Institute of Research and Education|San Francisco Veterans Affairs Medical Center Traumatic Brain Injury (TBI)|Hazardous and Harmful Alcohol Use November 2012 Phase 4
NCT00236847 Johnson & Johnson Pharmaceutical Research & Development, L.L.C. Epilepsy|Epilepsies, Partial|Seizures December 1989 Phase 2
NCT00236756 Johnson & Johnson Pharmaceutical Research & Development, L.L.C. Epilepsy|Seizures August 1993 Phase 3
NCT00236730 Johnson & Johnson Pharmaceutical Research & Development, L.L.C. Epilepsy|Epilepsies, Partial|Seizures June 1988 Phase 2
NCT00286923 Emerald City Headache Organization|Ortho-McNeil Neurologics, Inc. Migraine|Chronic Headache February 2006
NCT00236886 Johnson & Johnson Pharmaceutical Research & Development, L.L.C. Epilepsy|Epilepsies, Partial|Epilepsy, Generalized|Seizures May 1998 Phase 3
NCT00240721 Johnson & Johnson Pharmaceutical Research & Development, L.L.C. Bipolar Disorders|Mood Disorders|Affective Disorders, Psychotic October 2000 Phase 3
NCT00236691 Johnson & Johnson Pharmaceutical Research & Development, L.L.C. Epilepsy|Epilepsies, Partial|Seizures July 1988 Phase 2
NCT00236873 Johnson & Johnson Pharmaceutical Research & Development, L.L.C. Epilepsy|Epilepsies, Partial|Seizures October 1989 Phase 2
NCT00210535 Johnson & Johnson Pharmaceutical Research & Development, L.L.C. Migraine|Vascular Headaches June 2005 Phase 3
NCT00237289 Ortho-McNeil Neurologics, Inc. Bipolar Disorder October 2001 Phase 3
NCT00231634 Johnson & Johnson Pharmaceutical Research & Development, L.L.C. Obesity|Diabetes Mellitus, Type 2|Diabetes Mellitus, Adult-Onset May 2001 Phase 3
NCT00236860 Johnson & Johnson Pharmaceutical Research & Development, L.L.C. Epilepsy|Epilepsies, Partial|Seizures May 1989 Phase 2
NCT00769158 Bankole Johnson|University of Virginia Alcoholism October 2008 Phase 1
NCT00210873 Johnson & Johnson Pharmaceutical Research & Development, L.L.C.|Ortho-McNeil Neurologics, Inc. Migraine February 2004 Phase 3
NCT01114854 Supernus Pharmaceuticals, Inc. Epilepsy June 2010 Phase 1
NCT00210860 Johnson & Johnson Pharmaceutical Research & Development, L.L.C.|Ortho-McNeil Neurologics, Inc. Migraine September 2004 Phase 3
NCT00210912 Johnson & Johnson Pharmaceutical Research & Development, L.L.C.|Ortho-McNeil Neurologics, Inc. Migraine September 2003 Phase 3
NCT00329407 Boston University|National Institute on Alcohol Abuse and Alcoholism (NIAAA) Alcoholism September 2003 Phase 4
NCT00113815 Johnson & Johnson Pharmaceutical Research & Development, L.L.C. Partial Seizure Disorder|Epilepsy|Seizures May 2005 Phase 3
NCT00236626 Johnson & Johnson Pharmaceutical Research & Development, L.L.C. Obesity|Diabetes Mellitus, Type 2|Diabetes Mellitus, Adult-Onset April 2000 Phase 2
NCT00158002 Monarch Medical Research|Ortho-McNeil Neurologics, Inc. Basilar Migraine February 2004 Phase 2
NCT00208130 Creighton University|Ortho-McNeil Janssen Scientific Affairs, LLC Post-Traumatic Stress Disorder October 2001 Phase 4
NCT00203190 Thomas Jefferson University|Ortho-McNeil Neurologics, Inc. Cluster Headache September 2004 Phase 4
NCT00261469 Janssen-Ortho Inc., Canada Headache April 2003 Phase 2
NCT00131443 Monarch Medical Research|Ortho-McNeil Neurologics, Inc. Basilar Migraine February 2004 Phase 2|Phase 3
NCT00212810 Ortho-McNeil Neurologics, Inc. Migraine|Headache|Classic Migraine|Common Migraine September 2005 Phase 4
NCT00231647 Johnson & Johnson Pharmaceutical Research & Development, L.L.C. Obesity|Diabetes Mellitus, Type 2|Diabetes Mellitus, Adult-Onset February 2004 Phase 2
NCT01426542 University of California, Davis Cyanotic Congenital Heart Disease March 2011 Phase 1
NCT00187928 University of Florida|Ortho-McNeil Pharmaceutical Obsessive-Compulsive Disorder January 2003 Phase 3
NCT00204386 University of Oklahoma|Ortho-McNeil Neurologics, Inc. Posttraumatic Stress Disorder September 2002 Phase 2|Phase 3
NCT00236496 Johnson & Johnson Pharmaceutical Research & Development, L.L.C.|Ortho-McNeil Neurologics, Inc. Essential Tremor October 2001 Phase 3
NCT00237302 Ortho-McNeil Neurologics, Inc. Migraine July 2001 Phase 3
NCT00307619 Janssen-Cilag Farmaceutica Ltda. Binge Eating November 2003 Phase 3
NCT00210496 Janssen-Ortho LLC|Johnson & Johnson Pharmaceutical Research & Development, L.L.C. Migraine|Classic Migraine|Common Migraine June 2005 Phase 4
NCT00236639 Johnson & Johnson Pharmaceutical Research & Development, L.L.C. Obesity July 2000 Phase 3
NCT00752466 Johnson & Johnson Pharmaceutical Research & Development, L.L.C.|Jan-Cil Italy|Jan-Cil Spain|Jan-Cil UK|Jan-Cil Switzerland Human Volunteers|Migraine March 2003 Phase 1
NCT00236613 Johnson & Johnson Pharmaceutical Research & Development, L.L.C. Obesity September 2000 Phase 2
NCT03176953 VA Office of Research and Development|University of California, San Diego PTSD and Alcohol Use Disorder November 1, 2017 Phase 2|Phase 3
NCT00231621 Johnson & Johnson Pharmaceutical Research & Development, L.L.C. Obesity|Hyperlipidemia|Hypertriglyceridemia May 2001 Phase 3
NCT00236561 Johnson & Johnson Pharmaceutical Research & Development, L.L.C. Migraine|Common Migraine|Classic Migraine|Headache April 2001 Phase 3
NCT00884884 National Institute on Alcohol Abuse and Alcoholism (NIAAA)|Brown University Alcohol Dependence September 2007 Phase 2|Phase 3
NCT00231530 Johnson & Johnson Pharmaceutical Research & Development, L.L.C. Obesity|Diabetes Mellitus, Type 2|Diabetes Mellitus, Adult-Onset January 2001 Phase 3
NCT00236665 Johnson & Johnson Pharmaceutical Research & Development, L.L.C. Obesity|Hypertension March 2001 Phase 3
NCT00206336 Baylor College of Medicine|Ortho-McNeil Janssen Scientific Affairs, LLC Tourette Syndrome October 2004 Phase 3
NCT02040311 University of Copenhagen|R W Johnson Pharmaceutical Research Institute Obesity August 2000 Phase 4
NCT00210808 Johnson & Johnson Pharmaceutical Research & Development, L.L.C.|Ortho-McNeil Neurologics, Inc. Obesity|Binge-Eating Disorder September 2003 Phase 2|Phase 3
NCT00236600 Johnson & Johnson Pharmaceutical Research & Development, L.L.C. Obesity August 2000 Phase 3
NCT00210925 Johnson & Johnson Pharmaceutical Research & Development, L.L.C. Alcoholism March 2004 Phase 2
NCT00236717 Johnson & Johnson Pharmaceutical Research & Development, L.L.C. Epilepsy|Seizures September 1997 Phase 3
NCT00296959 University Health Network, Toronto Parkinson's Disease September 2004 Phase 2
NCT00231660 Johnson & Johnson Pharmaceutical Research & Development, L.L.C. Obesity|Diabetes Mellitus, Type 2|Diabetes Mellitus, Adult-Onset October 2000 Phase 3
NCT00297323 Janssen Cilag Pharmaceutica S.A.C.I., Greece Seizures, Epileptic June 2005
NCT01030094 Janssen Korea, Ltd., Korea Seizures|Convulsions|Epilepsy|Osteopenia|Osteoporosis February 2007 Phase 4
NCT00210782 Johnson & Johnson Pharmaceutical Research & Development, L.L.C.|Ortho-McNeil Neurologics, Inc. Epilepsy June 2004 Phase 3
NCT01439438 GlaxoSmithKline Epilepsy, Tonic-Clonic July 22, 2011 Phase 1
NCT00223639 Bankole Johnson|National Institute on Alcohol Abuse and Alcoholism (NIAAA)|National Institutes of Health (NIH)|University of Virginia Alcoholism September 2005 Phase 2
NCT00518466 VIVUS, Inc. Obesity July 2007 Phase 1
NCT00210821 Johnson & Johnson Pharmaceutical Research & Development, L.L.C.|Ortho-McNeil Neurologics, Inc. Migraine|Headache February 2004 Phase 3
NCT01811940 New York State Psychiatric Institute|National Institute on Drug Abuse (NIDA) Cocaine Dependence July 2013 Phase 2|Phase 3
NCT01889602 University of Minnesota - Clinical and Translational Science Institute Cognitive Deficits July 2013 Phase 4
NCT00004776 National Center for Research Resources (NCRR)|University of California, Los Angeles|Office of Rare Diseases (ORD) Lennox-Gastaut Syndrome November 1993 Phase 3
NCT00065923 Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) Prader-Willi Syndrome|Self-Injurious Behavior July 2002
NCT00206323 Baylor College of Medicine|Ortho-McNeil Janssen Scientific Affairs, LLC Tourette Syndrome September 2004 Phase 3
NCT00862563 Boston Medical Center|National Institute on Alcohol Abuse and Alcoholism (NIAAA) Alcoholism|Alcohol Dependence|Alcohol Abuse May 2009 Phase 2
NCT00154076 Eisai Korea Inc.|Eisai Inc. Epilepsy September 2005 Phase 4
NCT00432549 The New England Center for Headache, P.C.|Ortho-McNeil Neurologics, Inc. Analgesic Rebound Headache January 2007 Phase 4
NCT00006205 Bankole Johnson|National Institute on Alcohol Abuse and Alcoholism (NIAAA)|University of Virginia Alcoholism March 2005 Phase 2
NCT01581281 Children's Hospital Medical Center, Cincinnati|National Institute of Neurological Disorders and Stroke (NINDS) Migraine|Migraine Disorders|Headache June 2012 Phase 3
NCT02553824 Stanford University Binge Eating Disorder|Bulimia Nervosa July 2015 Phase 1
NCT00855738 Pfizer Focal Epilepsy May 2007 Phase 4
NCT00571246 Elizabeth Ralevski|Yale University Alcohol Dependence|Post Traumatic Stress Disorder June 2012 Phase 3
NCT00396734 Hadassah Medical Organization Opioid-Related Disorders|Cocaine-Related Disorders April 2007
NCT01096420 Kuang Tien General Hospital Patients With Chronic Migraine August 2008
NCT02643719 New York University School of Medicine Migraine December 2015
NCT00772031 Anne Lindblad|National Institute of Neurological Disorders and Stroke (NINDS)|Ortho-McNeil Janssen Scientific Affairs, LLC|The EMMES Corporation Chronic Migraine October 2008 Phase 3
NCT00208858 Emory University Tobacco Use Disorder December 2004 Phase 2
NCT00563459 SK Life Science Epilepsy|Seizures November 2007 Phase 3
NCT02635386 Woman's|AstraZeneca Polycystic Ovary Syndrome|Obesity March 2016 Phase 3
NCT00862095 Madigan Army Medical Center|U.S. Army Medical Research and Materiel Command Headache June 2008 Phase 4
NCT00600067 VIVUS, Inc.|Synteract, Inc.|Sentrx Diabetes January 2008 Phase 2
NCT01161017 Rambam Health Care Campus Migraine July 2008
NCT02301416 Wake Forest University Health Sciences|VIVUS, Inc. Obesity|Metabolic Surgery|Weight Loss|Bariatric Surgery Procedures December 2014
NCT02645370 Xijing Hospital|Ecion Pharmaceutical CO..LTD Migraine February 2016 Phase 1
NCT02945839 New York University School of Medicine Migraine December 2016
NCT00563368 VIVUS, Inc.|Medpace, Inc. Obesity December 2007 Phase 3
NCT00554216 VIVUS, Inc.|Medpace, Inc. Obesity November 2007 Phase 3
NCT00768209 VIVUS, Inc.|Covance|Sentrx Hepatic Impairment October 2008 Phase 1
NCT01351753 University of Iowa Obesity|Metabolic Syndrome X March 2011 Phase 2
NCT00777218 University of South Alabama Migraine August 2007
NCT00004807 Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|Johns Hopkins University|Office of Rare Diseases (ORD) Rett Syndrome January 1995
NCT03196466 Assistance Publique - Hôpitaux de Paris Epilepsy June 19, 2017
NCT02403687 Express Specialty Pharmacy Arthritis|Tendonitis|Gout|Radiculopathy|Muscle Spasms|Synovitis|Migraine|Headache June 2015
NCT02374567 Hannover Medical School Dementia|Depression|Schizophrenia|Psychosomatic Disorders|Anxiety Disorders January 2015 Phase 3
NCT02707965 Food and Drug Administration (FDA)|University of Maryland Epilepsy July 2017 Phase 4
View MoreCollapse
References
Molecular Weight

339.36

Formula

C₁₂H₂₁NO₈S

CAS No.

97240-79-4

Storage
Powder -20°C 3 years
  4°C 2 years
In solvent -80°C 6 months
  -20°C 1 month
Shipping

Room temperature in continental US; may vary elsewhere

Solvent & Solubility

10 mM in DMSO

* "<1 mg/mL" means slightly soluble or insoluble. "≥" means soluble, but saturation unknown.

Inquiry Online

Your information is safe with us. * Required Fields.

Product name

 

Salutation

Applicant name *

 

Email address *

Phone number

 

Organization name *

Country *

 

Requested quantity *

Remarks

Bulk Inquiry

Inquiry Information

Product Name:
Topiramate
Cat. No.:
HY-B0122
Quantity: